NASDAQ: JUNS
Jupiter Neurosciences Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their JUNS stock forecasts and price targets.

Forecast return on equity

Is JUNS forecast to generate an efficient return?

Company
N/A
Industry
1.15%
Market
136.42%

Forecast return on assets

Is JUNS forecast to generate an efficient return on assets?

Company
-172.93%
Industry
-13.21%
JUNS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

JUNS earnings per share forecast

What is JUNS's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.06
Avg 2 year Forecast
-$0.27

JUNS revenue forecast

What is JUNS's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$12.4M+56,676.47%
Avg 2 year Forecast
$7.5M+34,332.92%
JUNS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

JUNS revenue growth forecast

How is JUNS forecast to perform vs Biotechnology companies and vs the US market?

Company
56,676.47%
Industry
29.92%
Market
171.4%
JUNS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
JUNS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

JUNS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
JUNS$0.39N/AN/A
CYCN$3.26N/AN/A
INAB$1.50$6.00+300.00%Buy
MBRX$2.51$22.00+776.49%Buy
BLRX$2.86N/AN/A

Jupiter Neurosciences Stock Forecast FAQ

What is JUNS's earnings growth forecast for 2026-2027?

(NASDAQ: JUNS) Jupiter Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 20.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,431.06%.

Jupiter Neurosciences's earnings in 2026 is -$8,644,897.On average, 3 Wall Street analysts forecast JUNS's earnings for 2026 to be $2,220,413, with the lowest JUNS earnings forecast at $2,133,338, and the highest JUNS earnings forecast at $2,285,719.

In 2027, JUNS is forecast to generate -$9,621,788 in earnings, with the lowest earnings forecast at -$9,244,463 and the highest earnings forecast at -$9,904,782.

If you're new to stock investing, here's how to buy Jupiter Neurosciences stock.

What is JUNS's revenue growth forecast for 2026-2027?

(NASDAQ: JUNS) Jupiter Neurosciences's forecast annual revenue growth rate of 56,676.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 171.4%.

Jupiter Neurosciences's revenue in 2026 is $21,796.On average, 3 Wall Street analysts forecast JUNS's revenue for 2026 to be $448,980,494, with the lowest JUNS revenue forecast at $431,347,805, and the highest JUNS revenue forecast at $462,186,869.

In 2027, JUNS is forecast to generate $272,290,796 in revenue, with the lowest revenue forecast at $261,624,108 and the highest revenue forecast at $280,308,953.

What is JUNS's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: JUNS) forecast ROA is -172.93%, which is lower than the forecast US Biotechnology industry average of -13.21%.

What is JUNS's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: JUNS) Jupiter Neurosciences's current Earnings Per Share (EPS) is -$0.25. On average, analysts forecast that JUNS's EPS will be $0.06 for 2026, with the lowest EPS forecast at $0.06, and the highest EPS forecast at $0.06. In 2027, JUNS's EPS is forecast to hit -$0.27 (min: -$0.25, max: -$0.27).

What is JUNS's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: JUNS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.